Themis Medicare gets DCGI’s add on approval for ‘Viralex’

18 May 2022 Evaluate

Themis Medicare has received add on approval for drug Viralex by the Drug Controller General of India (DCGI) for treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

Viralex (Inosine Pranobex) is an immunomodulatory agent with broad spectrum antiviral properties. Earlier, Viralex was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two Randomized controlled trials (RCT) in 499 Indian patients. Viralex would be available on prescription.

Viralex strengthens the immune system through modulation of T-cell proliferation, T-cell function, natural killer cell activity, phagocytosis, and also by modulating certain cytokines, and enhances body's immune response to various viral infections. NK cells are the first line defense against viral infections. Viralex enhances human NK cell cytotoxicity in two ways by increasing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.


Themis Medicare Share Price

262.85 0.50 (0.19%)
01-Nov-2024 18:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1860.00
Dr. Reddys Lab 1259.10
Cipla 1562.15
Lupin 2203.00
Zydus Lifesciences 1003.35
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.